$1.20-0.01 (-0.83%)
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. in the Healthcare sector is trading at $1.20. Wall Street consensus targets $4.00 (1 analysts), implying a +233.3% move over the next 12 months. The stock is currently near its 52-week low of $1.10, remaining 53.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment pro...